FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...

BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders and autoimmune therapeutics, today ...

Study in Lancet Digital Health represents the largest real-world evaluation of stroke AI imaging, encompassing data from more than 450,000 patients admitted to 107 NHS England hospitals over a 5-year ...

New research out of the University of Iowa is reshaping what it means to live with cystic fibrosis, a genetic disease that ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, ...

Columnist Samuel Kirton shares his emergency "go bag" checklist of things he brought when he received a bilateral lung ...

Researchers from the Germans Trias i Pujol Research Institute (IGTP) have published a review analyzing the therapeutic ...

Researchers created a highly efficient gene-editing method that fixes multiple DNA mutations in a single step. The breakthrough could revolutionize genetic medicine by making treatments for complex ...

Nervous around needles and blood? Sweat tests may replace blood tests in the future, according to new research.

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...